Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial

Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial

This study investigated the gut microbiota and short chain fatty acids (SCFAs) characteristics of subjects with obesity from Xinjiang in northwestern China, a region with a multiethnic culture and characteristic lifestyle, and to explore the potential microbes that respond to a 12-wk medication of o...

Full description

Bibliographic Details
Main Authors: Jin Jin, Ruyue Cheng, Yan Ren, Xi Shen, Jiani Wang, Yigui Xue, Huimin Zhang, Xiuhua Jia, Tingting Li, Fang He, Haoming Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
gut microbiota
SCFAs
orlistat
ezetimibe
obesity
metabolism
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.732541/full

Similar Items

Similar Items